How Much Upside Is Left In Regeneron Stock?
Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo